Abstract:Dear Editor, It was proposed by Haider and Ashraf1 that cytokine and growth factor mediated mobilization of endogenous mesenchymal stem cells from their bone marrow niches for homing into the infarcted myocardium could be a better therapeutic strategy than the explantation and subsequent injection of these cells (either autologous or from a donated allogenic source) directly into the damaged heart.2 Besides being less invasive to the patient, it was argued that this approach would obviate the need for ex vivo processing of the putative stem cells, which could in turn reduce the risk of nonspecific differentiation into undesired lineages at the transplantation site.3–5 Nevertheless, such an approach could be severely hampered by the age related decline in the regenerative capacity of the putative mesenchymal stem cell population within the bone marrow, as has been demonstrated by a number of studies.6,7 It must be remembered that the overwhelming majority of myocardial infarct cases occur in the older segment of the population.8 Quarto and colleagues6 demonstrated in a rat model that there was an age associated decline in the ability of marrow stromal cells to repair bone, which could be the underlying cause of age related osteodegenerative diseases. Subsequently, D’Ippolito and colleagues7 reported a similar finding with the human model. This would be expected because, with increasing age, the putative mesenchymal stem cell population within the bone marrow would have gone through more rounds of cell division, in addition to having been exposed to free radicals and metabolic toxins over a longer lifespan. Hence it is no surprise that there is a gradual decline in their regenerative capacity with increasing age. Although there have been no studies to date that have conclusively demonstrated an age associated decline in the capacity of bone marrow cells to repair the infarcted heart, we could make such a conjecture based upon extrapolation from the bone repair model.6,7 The obvious solution to overcome this age related decline in regenerative capacity would be to look at donated allogenic sources of stem cells for myocardial repair. In this regard, human embryonic stem (hES) cells or their differentiated progenies would hold much promise because these potentially represent an abundant and readily available source of transplantable cells. Recently, Zandstra and colleagues9 successfully developed a scalable, robust, and reproducible process for obtaining purified cardiomyocytes from hES cells. Nevertheless, the immunologic barrier10 probably represents the most formidable challenge to the allogenic transplantation of hES cells or their differentiated progenies into the infarcted myocardium. It is hoped that this could somehow be overcome in the near future. Boon Chin Heng* Eugene Kwang-Wei Sim† Tong Cao* *Stem Cell Laboratory, Faculty of Dentistry, †Department of Surgery, Faculty of Medicine National University of Singapore.

[Stem cell therapy for cardiovascular diseases. Experiences in Düsseldorf]

Reply to Letter from Drs. Haider and Ashraf

Statin and Stromal Cell-Derived Factor-1 Additively Promote Angiogenesis

Cardiac-derived stem cell-based therapy for heart failure: progress and clinical applications.

Angiotensin Receptor Type 2 Stimulation Increases the Migration of Bone-Marrow Mononuclear Cells into the Infarcted Myocardium and Improves Heart Function

[A Prospective, Randomized, Controlled Trial of Autologous Mesenchymal Stem Cells Transplantation for Dilated Cardiomyopathy].

The development of autologous mesenchymal stem cell transplantation in the treatment of myocardial infarction

Stem Cell Therapy For Ischemic Heart Diseases

Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery.

Effects of stem cells on non-ischemic cardiomyopathy: a systematic review and meta-analysis of randomized controlled trials.

The Recent Advances in Cell Delivery Approaches, Biochemical and Engineering Procedures of Cell Therapy Applied to Coronary Heart Disease

Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction

Stem Cell Therapy in Heart Diseases – Cell Types, Mechanisms and Improvement Strategies

Bone marrow-derived stem/progenitor cells: their use in clinical studies for the treatment of myocardial infarction

An acute immune response underlies the benefit of cardiac stem cell therapy

Cellular Cardiomyoplasty Using Different Stem Cells in a Single Center

Intracoronary Administration of Autologous Adipose Tissue-Derived Stem Cells Improves Left Ventricular Function, Perfusion, and Remodelling after Acute Myocardial Infarction.

Autologous bone marrow cell therapy for peripheral arterial disease

Stem Cell Therapy against Ischemic Heart Disease

Autologous Transplantation of Bone Marrow/Blood-Derived Cells for Chronic Ischemic Heart Disease: A Systematic Review and Meta-analysis

A novel approach to transplanting bone marrow stem cells to repair human myocardial infarction: delivery via a noninfarct-relative artery.